Left Menu
Development News Edition

FDA to restrict ingredients for bulk drug compounding

The FDA was required to establish a list of substances those facilities could use for bulk compounding that met a “clinical need” but it has yet to finalize one.

FDA to restrict ingredients for bulk drug compounding
The FDA was required to establish a list of substances those facilities could use for bulk compounding that met a “clinical need” but it has yet to finalize one.(Image credit: Reuters)

The US Food and Drug Administration on Friday took steps to restrict what pharmaceutical ingredients large compounding pharmacies can use to manufacture drugs in bulk that do not go through the agency's approval processes.

The agency issued draft guidance that officials said prioritized the use of FDA-approved drugs over more risky, custom-made medicines produced in bulk by certain compounding pharmacies for hospitals and doctors' offices.

It marked the latest effort to regulate the industry following a fungal meningitis outbreak in 2012 linked to tainted drugs made in bulk by a compounding pharmacy that sickened 793 people, including 76 who died.

The guidance, if finalized, would limit the raw substances that large compounding pharmacies are known as "outsourcing facilities" can use to make medicines in bulk that do not go through the FDA safety review process.

The FDA said it would only allow a raw substance to be used if a clinical need was established showing why an FDA-approved drug could not be used to make a compounded medication by, for example, diluting or crushing it.

"The safest alternative is always an FDA approved product," FDA Commissioner Scott Gottlieb said.

Gottlieb said he expected the number of substances that can be used will shrink from the nearly 200 currently permitted under an interim policy.

Compounding traditionally involves mixing tailored doses for particular patients to address specific needs, such as removing a dye to treat someone with an allergy.

By 2012, the practice had mushroomed, with some pharmacies selling thousands of doses of regularly used mixtures for physicians to keep for future use.

The outbreak tied to Massachusetts-based New England Compounding Center prompted Congress in 2013 to pass a law aimed at bringing under FDA oversight more compounding pharmacies typically regulated by states.

It established "outsourcing facilities" that could register with the FDA. Those roughly 70 facilities can sell products in bulk without individual prescriptions while following federal manufacturing standards.

The FDA was required to establish a list of substances those facilities could use for bulk compounding that met a "clinical need" but it has yet to finalize one.

Under an interim policy, it allowed the use of substances that compounders could nominate for eventual inclusion on the list that had no major safety issues.

That policy prompted a lawsuit in October by drugmaker Endo International Plc, who claimed the FDA was authorizing the bulk compounding of hundreds of drugs without proper evaluation

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)



Hyderabad Encounter: Time to review modern judiciary and restore people’s confidence

Its probably for the first time in the history of independent India, the parliamentarians, chief ministers and ministers in the Union and State governments are openly supporting an encounter. This indicates the people from top to bottom hav...

What happens to your outstanding loans if the bank falls?

... ...

Time for a change! Innovations to stop the growing plastic pollution

As the planet is drowning in plastic pollution, many new innovative approaches and solutions have emerged to effectively deal with the menace....

How to avoid fake universities and fishing bait like Farmington

As education sharks are roaming around to prey, we present a guide on how to mitigate hunters and reach to a genuine universityinstitute. In this era of commercialization of education, the fake universities and economic frauds in educationa...


Latest News

Maybe we'll get it this time: Ritesh Sidhwani on 'Gully Boy' Oscar campaign

Producer Ritesh Sidhwani says the Gully Boy team is leaving no stone unturned to make sure the Ranveer Singh-starrer drama gets in the forefront at the Oscars race. The film has been selected as Indias official entry in the International Fe...

China's blue-chips end lower after weak export data

Chinas blue-chip stocks closed lower on Monday after latest trade data highlighted persistent headwinds for the countrys manufacturers amid a prolonged Sino-U.S. trade war. The blue-chip CSI300 index fell 0.2 to 3,895.45, while the Shangha...

When you deal with history, difficult to cut things: Kriti on length of 'Panipat'

Actor Kriti Sanon says it was nearly impossible for the team of Panipat to trim down its run-time because when one deals with history, its difficult to cut a lot of events. Directed by Ashutosh Gowariker, Panipat released last Friday. The A...

Satellite images show N.Korea tried out rocket engine in 'very important' test -experts

Satellite imagery captured before and after North Korea conducted what it called a very important test at its missile launch site suggested it had tested a rocket engine, experts said on Monday.It was the latest of a series of weapons tests...

Give Feedback